Posts Tagged ‘ judge Goodwin ’

Question: Which Transvaginal Mesh Trials are Next?

Feb 20th, 2013 | By
Question: Which Transvaginal Mesh Trials are Next?

MDND (Mesh Medical Device News Desk) and its FB Page have been receiving a lot of questions about which trials are scheduled to follow Linda Gross v. Ethicon, which on Thursday, February 28 resulted in an $11.1 million award to Linda and Jeff Gross. The award includes $7.76 million in punitive damages. See story here.
[continue reading...]



Breaking News! Johnson & Johnson’s Ethicon Plans to Pull Plug on Four Transvaginal Meshes!

Jun 4th, 2012 | By
Breaking News! Johnson & Johnson’s Ethicon Plans to Pull Plug on Four Transvaginal Meshes!

June 4, 2012 ~ Breaking news!  Bloomberg is reporting (here) that Johnson & Johnson (J&J) has requested the paperwork to stop selling four different types of transvaginal mesh in the face of hundreds of lawsuits. The Ethicon unit of J & J told a federal judge in West Virginia that it has requested the official
[continue reading...]



Litigation: Vaginal Mesh Status Conference May 2012

May 27th, 2012 | By
Litigation: Vaginal Mesh Status Conference May 2012

May 27, 2012 ~ The Honorable Judge Joseph R. Goodwin is overseeing all four vaginal mesh MDLs (multidistrict litigation) in his U.S. District Court for the Southern District of West Virginia. A status conference was held Thursday, May 24, 2012, in the U.S. Courthouse in Charleston, West Virginia to coordinate the discovery process and set
[continue reading...]



We hope you find this a helpful resource. National News Editor, Jane Akre, began MDND with the hope of providing the latest news, information and perspective from the regulatory, industry and patient point of view, something that goes under-reported in much of the coverage of medical devices. The public is just now becoming aware that many devices do not undergo the same scrutiny as prescription drugs and are instead grandfathered in under an FDA loophole that has gone largely unchanged since the 1970s. As a result, patients become the post-market clinical trial subjects, and many suffer devastating and permanent injuries.